CAFC sides with Sandoz, Amgen’s state claims preempted by BPCIA
The Federal Circuit’s first decision under the Biologics Price Competition and Innovation Act (BPCIA) involved Zarxio, Sandoz’s Neupogen biosimilar product. Amgen v. Sandoz, 794 F.3d 1347 (Fed Cir. 2015). The BPCIA provides for an orderly exchange of IP information meant to streamline patent suits …